PRIMARY STUDY
A Single-Blind, Randomized, Placebo Controlled Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula C Sublingual +Drops in People with Post-Acute Coronavirus Disease 2019 Syndrome
Key Findings: Formula C, cannabidiol (CBD)-rich sublingual drops, effectively relieved many symptoms of post-acute COVID syndrome. However, the study failed to rule out the possibility that the terpene-rich placebo compound might have also played a role in the improvements.
Type of Study: Clinical Trial
Study Sample Size: 24
Study Result: Positive
Research Location(s): United States
Year of Pub: 2024
Cannabinoids Studied: Cannabidiol (CBD), Omega-3, Omega-6
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype III
Route of Administration: Sublingual/Oromucosal
Citation: Young TP, et al. A Single-Blind, Randomized, Placebo Controlled Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula C Sublingual +Drops in People with Post-Acute Coronavirus Disease 2019 Syndrome. Cannabis Cannabinoid Res. 2024; 9:282-292. doi: 10.1089/can.2022.0135
Authors: Young TP, Erickson JS, Hattan SL, Guzy S, Hershkowitz F, Steward MD
